Chad Shear

Chad represents pharmaceutical companies in high-stakes patent litigation in the US and abroad. He is known globally for successfully protecting intellectual property rights and assets for his clients in make-or-break disputes that determine returns on multibillion-dollar investments and decades of research.

Over the course of his career, Chad has represented clients involving some of the top drugs on the market, including name brands, such as Gilead Sciences’ Sovaldi, Harvoni, Epclusa, Ranexa, Vemlidy, Descovy, Odefsey and Descovy for PrEP; Dainippon Sumitomo Pharma’s Latuda and Aptiom; and Iroko Pharmaceuticals’ Zorvolex and Vivlodex. Many of Chad’s cases are global, often involving multiple jurisdictions and major markets in Europe, North America and the Asia-Pacific region. Even in the most challenging of circumstances, Chad is known for his approachability, pragmatism, legal and business acumen, unwavering dedication to his clients and unflappability.

Chad’s trial experience is unmatched. He has served as lead trial attorney or as a member of the trial team in nearly two dozen trials, including numerous Hatch-Waxman cases. He is well versed in representing clients across multiple venues and jurisdictions, including the US Patent Trial and Appeal Board, the European Patent Office (EPO) and the US Court of Appeals for the Federal Circuit. Chad provides strategic legal counsel on a wide range of business matters by combining his litigation experience, network of scientific and business experts, and detailed knowledge of clients’ companies. He speaks and writes frequently on issues such as biosimilars and generics, Hatch-Waxman litigation, Markman hearings, and biotechnology and pharmaceutical patent due diligence.

Chad also teaches life sciences trial and patent practice courses around the US. From 2001 to 2003, Chad clerked for Judge Haldane Robert Mayer of the US Court of Appeals for the Federal Circuit.